<DOC>
	<DOC>NCT01209806</DOC>
	<brief_summary>The purpose of this study is to determine whether the administration of PEG along with simethicone will reduce the incidence of colonic bubbles that interfere with polyp detection.</brief_summary>
	<brief_title>The Effects of Moviprep With Simethicone on Colonic Bubbles</brief_title>
	<detailed_description>evaluating if simethicone is better than placebo at decreasing gas in the colon at time of colonoscopy so that it is easier for the endoscopist to see polyps</detailed_description>
	<mesh_term>Aluminum hydroxide, magnesium hydroxide, drug combination</mesh_term>
	<mesh_term>Aluminum hydroxide, magnesium hydroxide, simethicone drug combination</mesh_term>
	<mesh_term>Simethicone</mesh_term>
	<mesh_term>TEMPO</mesh_term>
	<criteria>Elective outpatients undergoing colonoscopy using split dose PEGELS with sodium ascorbate and ascorbic acid Unable or unwilling to give informed consent Age &lt; 18 years Pregnant Breast feeding Established or suspected gastroparesis Pseudoobstruction established or suspected Severe constipation (&lt; 1 BM a week) Bowel obstruction Greater than 50% resection of colon Chronic nausea or vomiting Consumed &gt; 100% standard dose of PEGELS (i.e. more than 2L) G6PD deficiency PEG allergy Significant psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>